Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma.

Faisal M SanaiHassan O OdahKanan AlshammariAdnan AlzanbagiMurooj AlsubhiHani TamimAshwaq AlolayanAhmed AlshehriSaleh A Alqahthani

Published in: Cancers (2024)

Nivolumab is an effective second-line treatment option in patients with uHCC who progress on sorafenib, with significantly improved OS. These early real-life data offer encouraging results, similar to those shown in Phase I/IIa clinical trials. Further investigations are warranted for the use of nivolumab as a monotherapy.

Keyphrases

clinical trial
combination therapy
open label
electronic health record
big data
randomized controlled trial
radiation therapy
bone marrow
cell therapy